INS and cancer: Possible biological mechanisms of SGLT2I on reduction of cancer risk include reduction of glucose uptake of cancer cells, thereby increasing cell necrosis and reducing tumour growth [9], increased insulin sensitivity, and reduced chronic inflammation [10–12].